ENZYME REPLACEMENT THERAPY (ERT)

FOR GMI



CURE GM1 HAS ENABLED THERAPEUTIC DEVELOPMENT IN GMI GANGLIOSIDOSIS

ENZYME REPLACEMENT THERAPY IS A PROVEN MODALITY IN

LYSOSOMAL STORAGE DISEASE 17 ERTs have been approved for 12 LSDS with a remarkably high

PROOF OF CONCEPT HAS BEEN DEMONSTRATED · POC in two mouse models of disease Substrate reduction to near normal levels

approval rate

Behavioral analysis ongoing

CURF GM1 IS LAYING THE GROUNDWORK TO IND

Have identified a high producing cell line Currently manufacturing at small scale; plans in place for scaleup to generate material for IND-enabling tox and the clinic

 Pre-IND meeting planned for early 2026 PROJECTED WORLDWIDE REVENUE OF >\$300M FOR GM1 ERT

GM1 FRT curegm1.org/donate

I FARN MORE

READ MORE ABOUT GM1 FRT

> curegm1.org/ertproject

